Abstract
Anesthesia and surgery have been reported to produce long-term cognitive problems, and to accelerate neurodegenerative disorders in the elderly. In previous work, we found that inhaled anesthetics enhance fibril formation and cytotoxicity of amyloid β peptide. In this work we show that the inhaled anesthetics halothane (2-bromo-2-chloro-1,1,1- trifluoroethane) and isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) also favor intermediate oligomers of amyloid β1-40, and reduce solubility of amyloid β1-40 monomer. Size-exclusion chromatography, analytical ultracentrifugation and photo-induced cross-linking experiments indicate halothane enhancement of oligomeric species having molecular weight ∼44-100 kDa. Bis-ANS fluorescence experiments revealed that halothane stabilizes a population of diffusible oligomers relative to the monomer or the mature fibril. These data show that inhaled anesthetics lower the amyloid β1-40 concentration necessary to initiate oligomer formation, probably by preferential binding to intermediate oligomers en route to fibril formation.
Keywords: Alzheimer's disease, intermediates, protein cavities, analytical ultracentrifugation, bis-ANS fluorescence, neurodegeneration, inhaled anesthetics
Current Alzheimer Research
Title: Inhaled Anesthetic Modulation of Amyloid β 1-40 Assembly and Growth
Volume: 4 Issue: 3
Author(s): Anna Carnini, J.D. Lear and R.G. Eckenhoff
Affiliation:
Keywords: Alzheimer's disease, intermediates, protein cavities, analytical ultracentrifugation, bis-ANS fluorescence, neurodegeneration, inhaled anesthetics
Abstract: Anesthesia and surgery have been reported to produce long-term cognitive problems, and to accelerate neurodegenerative disorders in the elderly. In previous work, we found that inhaled anesthetics enhance fibril formation and cytotoxicity of amyloid β peptide. In this work we show that the inhaled anesthetics halothane (2-bromo-2-chloro-1,1,1- trifluoroethane) and isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) also favor intermediate oligomers of amyloid β1-40, and reduce solubility of amyloid β1-40 monomer. Size-exclusion chromatography, analytical ultracentrifugation and photo-induced cross-linking experiments indicate halothane enhancement of oligomeric species having molecular weight ∼44-100 kDa. Bis-ANS fluorescence experiments revealed that halothane stabilizes a population of diffusible oligomers relative to the monomer or the mature fibril. These data show that inhaled anesthetics lower the amyloid β1-40 concentration necessary to initiate oligomer formation, probably by preferential binding to intermediate oligomers en route to fibril formation.
Export Options
About this article
Cite this article as:
Anna Carnini , J.D. Lear and R.G. Eckenhoff , Inhaled Anesthetic Modulation of Amyloid β 1-40 Assembly and Growth, Current Alzheimer Research 2007; 4 (3) . https://dx.doi.org/10.2174/156720507781077278
DOI https://dx.doi.org/10.2174/156720507781077278 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design and Development of Novel Transdermal Nanoemulgel for Alzheimer’s Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations
Current Drug Delivery Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets De Novo and Molecular Target-Independent Discovery of Orally Bioavailable Lead Compounds for Neurological Disorders
Current Alzheimer Research Editorial (Thematic Issue: Global Trends for Nanotechnological Approaches in Various Health Issues - Part 1)
Current Drug Metabolism Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets A New Hypothesis of Pathogenesis Based on the Divorce between Mitochondria and their Host Cells: Possible Relevance for Alzheimers Disease
Current Alzheimer Research Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Potential Therapeutic Drugs and Methods for the Treatment of Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Physically Cross-linked Hydrogels of β -cyclodextrin Polymer and Poly(ethylene glycol)-cholesterol as Delivery Systems for Macromolecules and Small Drug Molecules
Current Drug Delivery A Novel Approach for Substitution of Sulfonate Group by (1H)-imidazole moiety: An Application for Synthesis of Novel Benzyl Imidazolyl carbamates
Letters in Organic Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Molecular Structure of Ionotropic Glutamate Receptors
Current Medicinal Chemistry Orally Administered Nanotherapeutics For Parkinson’s Disease: An Old Delivery System Yet More Acceptable
Current Pharmaceutical Design Blood-brain Barrier Drug Discovery for Central Nervous System Infections
Current Drug Targets - Infectious Disorders Multiple Intranigral Unilateral LPS Infusion Protocol Generates a Persistent Cognitive Impairment without Cumulative Dopaminergic Impairment
CNS & Neurological Disorders - Drug Targets Dietary Lipids and Alzheimer’s Disease
Current Alzheimer Research Plant Polyphenols as Neuroprotective Agents in Parkinson’s Disease Targeting Oxidative Stress
Current Drug Targets Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism